filesize急性淋巴细胞白血病的分子诊断和治疗研究
Acute Lymphoblastic Leukemia Rearch from Molecular Diagnosis to Treatment Optionsmillion的用法>october
Abstract:
Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy in children and remains a significant cau of morbidity and mortality in adults. The molecular diagnosis of ALL provides a preci understanding of the heterogeneous nature of the dia and helps to identify high-risk patients who require intensive treatment. Several molecular abnormalities have been identified, including mutations in leukemia-associated genes, chromosomal translocations, and gene fusions. The molecular alterations provide opportunities for the development of targeted therapies that can improve patients' outcomes. This review provides an overview of molecular diagnostic techniques and emerging targeted therapies that have shown promising results in the treatment of ALL.
1976 4 5
Keywords: Acute lymphoblastic leukemia, Molecular diagnosis, Targeted therapy, Chromosomal translocations, Gene fusions
Introduction
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the proliferation of immature lymphoid cells in the bone marrow, leading to the infiltration of other organs. ALL is the most common cancer in children, accounting for approximately 30% of all childhood malignancies worldwide. In adults, ALL is a rare dia accounting for only 20% of all leukemias. However, it remains a significant cau of morbidity and mortality, particularly in patients with relapd or refractory dia. The prognosis of ALL is influenced by veral factors, including age, initial respon to therapy, and the prence of specific genetic abnormalities. The development of molecular diagnostic techniques has led to a better understanding of the molecular heterogeneity of ALL and has paved the way for the development of targeted therapies.mold
英文鬼故事Molecular diagnosis of ALL
The diagnosis of ALL is bad on the prence of blast cells in the bone marrow or peripheral blood, along with clinical manifestations. Molecular diagnosis techniques have
lastresort
been developed to provide a better understanding of the molecular basis of the dia and to identify high-risk patients who require aggressive treatment. The techniques include cytogenetic analysis, fluorescence in situ hybridization (FISH), polymera chain reaction (PCR), and next-generation quencing (NGS).
Cytogenetic analysis is a classical technique that involves the visualization of chromosomal abnormalities using banding techniques. Chromosomal translocations involving the immunoglobulin and T-cell receptor genes are common in ALL and are associated with specific subtypes of the dia. For example, the t(9;22) Philadelphia chromosome is prent in approximately 25% of adult ALL cas and is associated with a poor prognosis. FISH is a more nsitive technique that allows the detection of chromosomal translocations, gene fusions, and copy number variations using fluorescent probes. PCR is a highly nsitive technique that amplifies specific DNA quences and is widely ud to detect fusion genes and minimal residual dia (MRD) in ALL patients. NGS is a next-generation quencing technique that allows the simultaneous detection of multiple mutations and copy number variations in a single assay, providing a comprehens
ive genomic analysis of the dia.
Targeted therapies in ALL
The identification of specific molecular abnormalities in ALL has led to the development of targeted therapies that can improve patients' outcomes. The success of targeted therapies in ALL depends on the identification of patient subgroups that are likely to benefit from the therapies, as well as the development of drugs that can target the specific molecular abnormalities.
Chromosomal translocations involving the B-cell receptor (BCR) and the T-cell receptor (TCR) genes are common in ALL and result in the formation of fusion proteins that drive leukemogenesis. Several drugs have been developed to target the fusion proteins, including imatinib and dasatinib, which target the BCR-Abl fusion protein, and ponatinib, which targets the T315I mutation in the BCR-Abl fusion protein.
十二月英文缩写Gene fusions involving the mixed-lineage leukemia (MLL) gene are common in infant ALL
and are associated with a poor prognosis. Several drugs have been developed to target MLL fusion proteins, including DOT1L inhibitors and CDK9 inhibitors, which target the epigenetic regulation of gene expression.
Conclusionsummerholiday
Molecular diagnosis techniques have provided a better understanding of the heterogeneous nature of ALL and have identified specific molecular abnormalities that can be targeted by drugs. The u of targeted therapies in ALL is still in its early stages, and more rearch is needed to identify patient subgroups that are likely to benefit from the therapies, as well as the development of new drugs that can target specific molecular abnormalities. The success of targeted therapies in ALL depends on a better understanding of the dia's biology and the development of personalized treatment strategies.Targeted therapies have revolutionized the treatment of veral cancers, including ALL. The therapies provide a more preci approach to cancer treatment by targeting specific molecular abnormalities that drive tumor growth and spread, while spari
ng normal tissue. Successful targeted therapies in ALL have led to improved outcomes for many patients, particularly tho with high-risk dia.hori
